Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215312) titled 'A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin' on Oct. 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Diabetes Mellitus, Type 2
Intervention:
Drug: LY3938577
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2025
Target Sample Size: 100
Countries of Recruitment:
United States
Argentina
United States
To know more, visit https://clinicaltrials.gov/study/N...